H. Brandhorst et al., Significant progress in porcine islet mass isolation utilizing liberase HIfor enzymatic low-temperature pancreas digestion, TRANSPLANT, 68(3), 1999, pp. 355-361
Background. Frequent success in human islet isolation is prevented by the l
arge variability of scarce organ donors; this favors the future utilization
of pigs as donors for clinical islet xenotransplantation. Porcine-specific
difficulties of islet isolation are attributed to the intrinsic fragility
of islets during pancreas digestion.
Methods. To preserve islet integrity during efficient pancreas dissociation
, porcine pancreata (n = 48) were distended after cold storage with cold Un
iversity of Wisconsin solution containing Liberase HI and digested at 24-28
degrees C using digestion-filtration. Pancreata distended with University
of Wisconsin solution containing well-proven crude collagenase and digested
at 32-34 degrees C served as controls (n = 46). Monolayer Ficoll-diatrizoa
te gradient purification was performed in a Cobe 2991.
Results. Purified yield of islet equivalents per pancreas (mean +/- SEM) wa
s almost doubled by Liberase HI compared with crude collagenase (526,480 +/
- 46,560 vs. 270,270 +/- 19,420; P < 0.0001) and also significantly increas
ed comparing islet equivalents per gram of pancreas (4,210 +/- 320 vs. 2,64
0 +/- 245; P = 0.0004). Islet integrity was better preserved during Liberas
e HI digestion compared with crude collagenase digestion as indicated by is
olation index (2.1 +/- 0.1 vs. 1.4 +/- 0.1; P < 0.0001). Purity, viability,
and in vitro function of islets did not differ between experimental groups
. Preserved in vivo function of islets isolated by Liberase HI was demonstr
ated after subcapsular transplantation into 16 diabetic nude rats.
Conclusions. If the problems related to xenograft rejection and xenosis cou
ld be solved, low-temperature digestion of porcine pancreata using Liberase
HI could serve as an essential prerequisite for successful 1:1 xenotranspl
antation of pig islets into type 1 diabetic human recipients.